Subscribe To Our Free Newsletter |
Ambuja a good buy on 5-10% correction; 12-15% upside possible in pharma: Hemang Jani
“If we see any minor correction in the names like Ambuja, that would be a good entry because having seen this kind of capital infusion and the expansion plans because of a huge amount of interest in this name both from institutional investors as well as retail, another 5-10% correction in Ambuja would be a good entry point for short and long-term investors.”